NASDAQ : SPRB
Spruce Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 46.82 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 134.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 133.33M |
| Enterprise Value | 44.70M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.87M |
| Shares Outstanding | 2.87M |
| Shares Change (YoY) | +149.79% |
| Shares Change (QoQ) | +77.18% |
| Owned by Insiders (%) | 3.45% |
| Owned by Institutions (%) | 51.05% |
| Float | 2.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.23 |
| Quick Ratio | 8.78 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -105.98% |
| Return on Assets (ROA) | -40.03% |
| Return on Invested Capital (ROIC) | -46.91% |
| Return on Capital Employed (ROCE) | -43.45% |
| Weighted Average Cost of Capital (WACC) | 22.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.33M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.30 |
| 52-Week Price Change | -60.69% |
| 50-Day Moving Average | 50.01 |
| 200-Day Moving Average | 55.78 |
| Relative Strength Index (RSI) | 52.07 |
| Average Volume (20 Days) | 78,569 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 522,120 |
| Short Previous Month | 431,541 |
| Short % of Shares Out | 18.17% |
| Short % of Float | 25.89% |
| Short Ratio (days to cover) | 5.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -22.95M |
| Operating Income | -39.93M |
| Pretax Income | -51.35M |
| Net Income | -51.35M |
| EBITDA | -39.04M |
| EBIT | -39.93M |
| Earnings Per Share (EPS) | -$36.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 96.30M |
| Total Debt | 7.67M |
| Net Cash | 88.62M |
| Net Cash Per Share | $30.84 |
| Equity (Book Value) | 83.73M |
| Book Value Per Share | 30.42 |
| Working Capital | 90.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -42.62M |
| Capital Expenditures | -145,000 |
| Depreciation & Amortization | 891,000 |
| Net Borrowing | 12.90M |
| Free Cash Flow | -42.77M |
| FCF Per Share | -$14.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -149.79% |
| Shareholder Yield | -149.79% |
| Earnings Yield | -77.71% |
| FCF Yield | -32.08% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $148.00 |
| Price Target Difference | 219.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:75 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |